Tachycardia-bradycardia syndrome
Conditions
Interventions
None listed
Sponsors
Juntendo University Graduate School of Medicine, Department of Cardiovascular Biology and Medicine, Shunsuke Kuroda
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following conditions will be included in this study: 1. Either of the following two criteria will be observed at the cessation of atrial ectopic tachycardia, atrial fibrillation, atrial flutter, or atrial tachycardia (supraventricular tachycardia) : 1-1. The sinus pause time after the cessation of supraventricular tachycardia is more than 5 seconds. 1-2. The sinus pause time after the cessation of supraventricular tachycardia is more than 3 seconds, and it causes by the sinus pause or it is plausible that the pauses cause symptoms related to tachycardia-bradycardia syndrome within the last three. 2. They are scheduled for either catheter ablation or pacemaker implantation therapy within the next three months. 3. Written consent for participation in the study can be obtained from the individual.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria from 1 to 7 will be excluded from this study: 1. Patients who have previously received any of the following treatments: Catheter ablation for atrial fibrillation, maze surgery, permanent pacemaker implantation, mechanical heart valve replacement surgery. ] 2. Patients with a left ventricular ejection fraction less than 40% 3. Patients exhibiting complete atrioventricular block, advanced atrioventricular block, or complete left bundle branch block 4. Patients with a disease prognosis estimated to be less than one year 5. Patients for whom catheter ablation or permanent pacemaker procedures are considered difficult due to anatomical reasons from previous medical history 6. Cases where responses to the Quality of Life (QoL) questionnaire are difficult due to dementia or similar conditions 7. Other patients whom the research leader determines to be inappropriate as study subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in quality of life assessment scale from before treatment to 6 months and 12 months after the initial pacemaker therapy or catheter ablation therapy, diagnosed as tachy-brady syndrome. This study will utilize either the AFEQT, the Short Form-12, or the EQ-5D-5L as the assessment tools for quality of life. | — |
Secondary
| Measure | Time frame |
|---|---|
| Complications during pacemaker or ablation therapy. Adverse events within 24 months after treatment, such as: Mortality, stroke, systemic embolism, major bleeding events, hospitalization for heart failure, syncope, pacemaker lead infection or extraction, or catheter ablation after the initial procedures. | — |
Countries
Japan
Contacts
Public ContactShunsuke Kuroda
Juntendo University Graduate School of Medicine Department of Cardiovascular Biology and Medicine
Outcome results
None listed